Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · July 10, 2023

Trastuzumab Biosimilar Plus Paclitaxel for HER2-Positive Recurrent or Metastatic Urothelial Carcinoma

ESMO Open

 

Additional Info

ESMO Open
Phase II study of a trastuzumab biosimilar in combination with paclitaxel for HER2-positive recurrent or metastatic urothelial carcinoma: KCSG GU18-18
ESMO Open 2023 Aug 01;8(4)101588, M Kim, JL Lee, SJ Shin, WK Bae, HJ Lee, JH Byun, YJ Choi, J Youk, CY Ock, S Kim, H Song, KH Park, B Keam

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading